

UNITED STATES INTERNATIONAL TRADE COMMISSION
Washington, D.C.

In the Matter of

**CERTAIN BOTULINUM TOXIN
PRODUCTS AND PROCESSES FOR
MANUFACTURING OR RELATING TO
SAME**

Investigation No. 337-TA-1313

**NOTICE OF A COMMISSION DETERMINATION TO EXTEND THE DUE DATE FOR
DETERMINING WHETHER TO REVIEW THE FINAL INITIAL DETERMINATION**

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

SUMMARY: Notice is hereby given that the U.S. International Trade Commission has determined to extend the due date for determining whether to review the final initial determination (“Final ID”) of the presiding administrative law judge (“ALJ”) from to September 27, 2024.

FOR FURTHER INFORMATION CONTACT: Ronald A. Traud, Esq., Office of the General Counsel, U.S. International Trade Commission, 500 E Street S.W., Washington, D.C. 20436, telephone (202) 205-3427. Copies of non-confidential documents filed in connection with this investigation may be viewed on the Commission’s electronic docket (EDIS) at <https://edis.usitc.gov>. For help accessing EDIS, please email EDIS3Help@usitc.gov. General information concerning the Commission may also be obtained by accessing its Internet server at <https://www.usitc.gov>. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission’s TDD terminal on (202) 205-1810.

SUPPLEMENTARY INFORMATION: The Commission instituted this investigation on May 5, 2022, based on a complaint filed on behalf of Medytox Inc. of the Republic of Korea (“Medytox”). 87 FR 26782, 26873 (May 5, 2022). The complaint alleged violations of subsection (a)(1)(A) of section 337 based on the importation into the United States, the sale for importation, or the sale within the United States after importation of certain botulinum toxin products and processes for manufacturing or relating to the same by reason of theft and conversion and misappropriation of trade secrets, the threat or effect of which is to destroy or substantially injure an industry in the United States. *Id.* The notice of investigation named as respondents Hugel, Inc. of the Republic of Korea; Hugel America, Inc. of Irvine, California (together, “Hugel”); and Croma Pharma GmbH of Leobendorf, Austria (“Croma,” and together with Hugel, “Respondents”). *Id.* The Office of Unfair Import Investigations (“OUII”) is participating in this investigation. *Id.*

On February 6, 2024, the investigation terminated as to Medytox's misappropriation of trade secrets allegations. Order No. 39 (Jan. 22, 2024), *unreviewed*, Comm'n Notice, EDIS Doc. ID 813405 (Feb. 6, 2024).

On June 10, 2024, the ALJ issued the Final ID. On June 24, 2024, Medytox filed a petition for Commission review of the Final ID that also included a request for oral argument, and Respondents filed a contingent petition for Commission review of the Final ID. On July 2, 2024, or July 8, 2024, the parties filed responses to the petitions.

The Commission has determined to extend the due date for determining whether to review the Final ID to September 27, 2024.

The Commission vote for this determination took place on August 9, 2024.

The authority for the Commission's determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in Part 210 of the Commission's Rules of Practice and Procedure (19 CFR Part 210).

By order of the Commission.

A handwritten signature in black ink, appearing to read 'Lisa R. Barton', enclosed within a large, loopy oval flourish.

Lisa R. Barton
Secretary to the Commission

Issued: August 9, 2024